Compare Amgen, Inc. (AMGN) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Futu Holdings Ltd — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Futu Holdings Ltd trades at $95.6 (market cap $13.51B). The key difference: Amgen, Inc. is far larger — about 14.5× Futu Holdings Ltd's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | FUTU | |
|---|---|---|
Market Cap | $196.12B | $13.51B |
Sector | Health | Financials |
52-Week High | $388.16 | $199.04 |
52-Week Low | $271.18 | $89.76 |
Enterprise Value | $241.41B | $13.36B |
Dividend Yield | 2.77% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Futu Holdings trades at $96.33, down 0.71% on the day, with a neutral technical signal and key support at $95. The company reported strong 2025 revenue of $22.85 billion and net income of $11.34 billion, with high profitability margins. However, recent earnings misses and a securities class action lawsuit have introduced uncertainty.
The outlook is mixed: solid fundamentals and a 'Buy' analyst consensus support upside, but legal risks and earnings volatility pose significant headwinds. Investors should weigh the attractive valuation against potential regulatory and litigation overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
